Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Venous Thrombosis 1Venous Thromboembolism 1Vascular Diseases 1Urogenital Neoplasms 1Thromboembolism 1Prostatic Neoplasms 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lymphoproliferative Disorders 1Lymphoma 1Lymphatic Diseases 1Lung Neoplasms 1Leukemia 1Intestinal Neoplasms 1Hemostatic Disorders 1Digestive System Neoplasms 1Colorectal Neoplasms 1Breast Neoplasms 1

Interventions

Azacitidine 160venetoclax 149Cytarabine 123Rituximab 94fludarabine 76Cyclophosphamide 70Imatinib Mesylate 59nilotinib 55ibrutinib 54Dasatinib 48obinutuzumab 47Bendamustine Hydrochloride 43Decitabine 39Daunorubicin 38idelalisib 31acalabrutinib 31Dexamethasone 29Chlorambucil 29Idarubicin 26gilteritinib 24Lenalidomide 23bosutinib 21asciminib 21ofatumumab 20blinatumomab 19pirtobrutinib 18fludarabine phosphate 18Vincristine 18zanubrutinib 16ublituximab 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Tinzaparin × Other hematologic neoplasm × Clear all
NCT03099031 2019-12-16

PREDICARE

LEO Pharma

Completed
420 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Breast Neoplasms, Digestive System Neoplasms, Intestinal Neoplasms, Leukemia, Lung Neoplasms, Lymphatic Diseases, Lymphoma, Lymphoproliferative Disorders, Multiple Myeloma, Myeloproliferative Disorders, Neoplasms, Prostatic Neoplasms, Thromboembolism, Urogenital Neoplasms, Vascular Diseases, Colorectal Neoplasms, Hemostatic Disorders, Venous Thrombosis, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡